Palisade Bio Inc. (PALI)
NASDAQ: PALIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PALI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $150.74M
- P/E (TTM)
- 0.91
- EPS (TTM)
- $0.92
- Dividend yield
- None
- 52-week range
- 0.8381 – 2.86
- Day range
- 0.8381 – 0.96
- Volume / Avg
- 3.19M / 3.19M
- Beta
- —
- Shares outstanding
- 179.28M
52-week range
PALI stock today
Shares of Palisade Bio (PALI) finished lower on Nov 20 at $0.8399, a drop of 9.24% or $0.0855 per share, versus the S&P 500's 3.70% decline. At this level, PALI sits near the bottom of its 52-week range of $0.8381 to $2.86: 70.6% below the high, set on Apr 22, 2026 and 0.2% above the low. PALI is down 64.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 60.6%.
Palisade Bio trades at 0.9x its trailing twelve-month earnings per share of $0.92.
Summary generated from market data by MetaCap's automated system. Methodology
About Palisade Bio
Company profilePalisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. J. D. Finley
- Headquarters
- Denver, CO
- Employees
- 14
- Website
- palisadebio.com
Financial highlights
Full financialsIn fiscal 2025, Palisade Bio generated $0 in revenue, up 0.0% from fiscal 2024. Palisade Bio reported a net loss of $16.8 million, compared with a loss of $14.4 million a year earlier. Diluted earnings per share came in at -$0.30.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $250.00K | $0 | — |
| Growth | — | -100.00% | — | — | — |
| Net income | $-16.78M | $-14.44M | $-12.30M | $-14.26M | $-26.62M |
| EPS (diluted) | $-0.30 | $-10.19 | $-27.01 | $-16.53 | $-169.74 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$8.70+935.84%
- Strong buy 3
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.07 vs $-0.06
- Surprise
- -16.67%
PALI news
All PALI news- Palisade Bio Reports Third Quarter 2026 Financial Results and Advances PALI-2108 Phase 2 Clinical Development ProgramsGlobeNewswire
- Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative ColitisGlobeNewswire
- Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026GlobeNewswire
- Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026GlobeNewswire
- Raymond James Initiates Coverage of Palisade Bio with OutperformNasdaq
Palisade Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs PALI |
| TARAProtara Therapeutics Inc. | 2.28 | -5.00% | $140.38M | vs PALI |
| CGENCompugen Ltd. | 1.84 | -2.13% | $174.29M | vs PALI |
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs PALI |
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs PALI |
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs PALI |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs PALI |
| IKTInhibikase Therapeutics Inc. | 1.32 | +1.54% | $185.16M | vs PALI |
Indexes, lists and sector
Palisade Bio stock FAQ
What is Palisade Bio's stock price today?
PALI last traded at $0.8399 as of Nov 20, 4:00 PM EST, down 9.24% on the day. Prices are delayed at least 15 minutes.
Does Palisade Bio pay a dividend?
No. Palisade Bio does not currently pay a regular cash dividend.
What is PALI's P/E ratio?
PALI trades at a trailing P/E ratio of 0.91.
Who is Palisade Bio's CEO?
Mr. J. D. Finley is the chief executive officer of Palisade Bio Inc., which has about 14 employees.
Has PALI ever split its stock?
Yes. The most recent PALI stock split was a 1-for-15 split on Apr 8, 2024, one of 5 splits on record.
What is the PALI 52-week high?
The 52-week high for PALI is $2.86 and the 52-week low is $0.8381. The stock is currently 70.6% below its high.